UNSPSC 51402603: Ipsapirone hydrochloride

This classification denotes a serotonin agonist and anxiolytic with the molecular formula C19H23N5O3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08R5U8PYVO, chemically known as 1,2-benzisothiazol-3(2h)-one, 2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-, 1,1-dioxide, monohydrochloride but more generally known as ipsapirone hydrochloride, which bears US NIH Compound Identifier 71187. Most nations, for tariff and trade purposes, schedule ipsapirone hydrochloride under HS 29341000 and SITC 51579.

As of Q4 2014, IPSAPIRONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ipsapirone hydrochloride bears US NLM identifiers UMLS ID C2346591 and NCI Concept Code C72812. SMILES: C1CCC2C(C1)C(=O)N(S2(=O)=O)CCCCN3CCN(CC3)C4NCCCN4.CL.

UNSPSC 51402603 Ipsapirone hydrochloride is a Commodity code under which state and local governments procure pharmaceutical products, though recent activity shows the code tagged to opportunities for naloxone and other therapeutic agents and multi-source generic pharmaceuticals rather than ipsapirone specifically. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances serving state agencies and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance). The work being solicited spans naloxone procurement for community health initiatives with quarterly delivery cycles, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceutical supply agreements through authorized wholesalers with competitive pricing models and compliance with FDA and Drug Supply Chain Security Act requirements.

Recent activity shows concentration in Florida and Minnesota, with market-intelligence solicitation from Texas. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and a two-year initial term with one-year renewal option. The Minnesota Department of Administration's Office of State Procurement, administering the multistate cooperative purchasing vehicle MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, and contract effectiveness July 1, 2026; evaluation weighted 75 percent on price competitiveness with 10 percent on fixed pricing and compliance weighted across administrative, EDI, and fee structure criteria. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, as preliminary market research on direct-to-manufacturer prescription program capabilities with no formal award timeline or budget specified at that stage.